You are seeing these quotes based on previous browsing related to sectors such as
Latest | Forecast | |
---|---|---|
Div Yield | 0.0% | 0.0% |
Div Cover | n/a | n/a |
Op Mrgn | -239.4% | -52.7% |
ROCE | 0.0% |
Latest | Forecast | |
---|---|---|
P/E | -0.4 | 0.0 |
PEG | 0.0 | -999,999.0 |
Price / Revenue | 1.2 | 0.5 |
Price / Book value | 1.1 |
Latest | Forecast | |
---|---|---|
Revenue | 138.0% | -64.2% |
PBT | 0.0% | n/a |
EPS | 0.0% | 892.1% |
DPS | n/a | 0.0% |
Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
---|---|---|---|---|---|---|---|---|
2019-12-31 | 0.72 | -9.07 | -7.55p | -22.4 | 0.0 | n/a | n/a | 0.0% |
2020-12-31 | 10.39 | -1.89 | -1.89p | -31.8 | 0.0 | n/a | n/a | 0.0% |
2021-12-31 | 1.52 | -19.91 | -10.00p | -4.3 | 0.0 | n/a | n/a | 0.0% |
2022-12-31 | 5.50 | -49.43 | -21.00p | -0.3 | 0.0 | n/a | n/a | 0.0% |
2023-12-31 | 13.09 | -32.38 | -5.00p | -1.3 | 0.0 | n/a | n/a | 0.0% |
Shield Therapeutics net sales grow in Q2, CEO stands down Sharecast News | 24 Jul |
---|---|
Shield Therapeutics reports strong US progress Sharecast News | 07 Dec |
Unaudited Q2 2024 Trading Update | 24-Jul-24 07:01 |
---|---|
Directorate Change | 24-Jul-24 07:01 |
$5.7m Milestone Monetization Agreement with AOP | 03-Jul-24 07:01 |
Results of 2024 Annual General Meeting | 20-Jun-24 16:26 |
New Drug Application for Accrufer® in South Korea | 28-May-24 07:02 |